Abstract
Cancer therapy duration is variable and may take years, adding a new challenge of maintaining the best life quality for cancer survivors. In cancer patients, late-onset toxicities have been reported with monoclonal antibodies and may involve several body organs or systems. They are defined as an autoimmune illnesses that can happen months to years after treatment discontinuation. Late-onset toxicities have become a focus of clinical care and related research. After cancer therapy is completed, the patient should receive longitudinal follow-up to detect these late effects as early as possible. The current review summarizes the recently reported late-onset toxicities of four classes of monoclonal antibodies (anti-CD52, anti-CTLA-4, anti-PD-1 and anti-CD20) with guidance for the diagnostic tools, appropriate management and treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1067-1083 |
| Number of pages | 17 |
| Journal | Immunotherapy |
| Volume | 14 |
| Issue number | 13 |
| DOIs | |
| State | Published - Sep 2022 |
Bibliographical note
Funding Information:The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.
Publisher Copyright:
© 2022 Future Medicine Ltd.
Keywords
- anti-CD20
- anti-CD52
- anti-CTLA-4
- delayed immune-related event
- immune checkpoints inhibitors
- late-onset toxicity
- monoclonal antibodies
PubMed: MeSH publication types
- Journal Article
- Review
